Avalo Therapeutics executes 1-for-240 reverse stock split to regain Nasdaq compliance

Avalo Therapeutics, Inc.

Reverse split effective 5:00 PM ET Dec 28, 2023; shares trade split-adjusted Dec 29 under AVTX.
Shares outstanding reduced from ~192.4M to ~801,611; fractional shares rounded up to whole share.
Split raises per-share price to satisfy Nasdaq Capital Market minimum bid price rule.
No change to authorized shares or par value; options/warrants adjusted proportionally.
New CUSIP 05338F306; Equiniti Trust Company acting as exchange agent.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Avalo Therapeutics, Inc.: Effected a reverse stock split at a ratio of 1-for-240 shares of common stock (effective 2023-12-28).

Change: charter amendment
Effective: 2023-12-28

Exact text from the filing

Avalo Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock at a ratio of one (1) share for every two hundred forty (240) shares outstanding

View on SEC.gov

188 governance changes filed in the last 30 days. Browse all governance changes →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-042817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.